Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of ABT-450/r, ABT-267, ABT-333, and ribavirin in genotype 1 chronic hepatitis C
2010-022455-31Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paritaprevir, ritonavir, glecaprevir, dasabuvir and ribavirin in chronic hepatitis C (CHC) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Sustained virologic response at 24 weeks post-treatment in treatment-naive subjects. Started Oct 2011; status: completed.
02
Drugs
paritaprevirritonavirglecaprevirdasabuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2010-022455-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022455-31.